Introduction. Seminomas are the most common testicular tumors. Initial therapy includes orchiectomy with resection of local lymph nodes, followed by adjuvant radiotherapy. Testicular tumors usually metastasize to retroperitoneal and mediastinal lymph nodes, lungs, liver, spleen, gastrointestinal tract, and adrenal glands. Bone metastases from testicular tumors are very rare, while seminoma metastasis to the bone marrow is a curiosity, without any references in the scientific literature. Case Report. A 66-year-old patient, previously treated for follicular non-Hodgkin lymphoma, was admitted due to complaints of malaise, abdominal and back pain, and hepatosplenomegaly. After examination and radiologically verified enlarged retroperitoneal lymph nodes, the patient was referred to a hematologist. Based on the patient?s medical history, a relapse of lymphoma was suspected, and bone marrow biopsy was performed. The hematoxylin-eosin staining of the biopsy sample showed diffuse large cell infiltrates with bright cytoplasm, polygonal nuclei and prominent nucleoli. By immunohistochemical staining, the cells showed positivity for cluster of differentiation 10, cluster of differentiation 117, octamer binding transcription factor 3/4, placental alkaline phosphatase, and cytokeratin 8/18, after which the diagnosis of seminoma metastasis to the bone marrow was made. Shortly after the histopathological diagnosis was made, the patient died. Conclusion. A seminoma is a testicular tumor with a favorable prognosis. Due to suppression of hematopoiesis, bone marrow metastases generally lead to the worst prognosis. The outcome of our patient highlights the importance of timely diagnosis and therapy, which would increase the chances of survival.

This paper seeks to present surgical procedures, results and complications of treatment of verrucous carcinoma (VC) of the vulva treated in at Gynecological and Obstetric Clinics within the Faculty of Medicine, University of Novi Sad (Serbia), as well as literature review of surgical treatment of VC. During the period of 15 years (2005 to 2019), we performed 76 surgeries of vulvar cancer, 9 (11.8%) due to VC of the vulva. In surgical treatment of VC vulva, we performed complete surgical excision of the tumor (3), complete surgical excision of the tumor with defect coverage using VY fasciocutaneous skin flap (2), simplex vulvectomy (2), radical hemivulvectomy (1) and radical vulvectomy (1). We came across 2 main complications (22.2%): suture bleeding within 12 hours after excision in 1 patient (11.1%) and lower extremity lymphoedema after inguinofemoral lymphadenectomy with ligation of the great saphenous vein in 1 patient (11.1%). In total number of 9 treated patients survival rate was 88.8% (8 patients) with death rate of 11.1% (1 patient) within 12 months after surgery. In 3 patients (33.3%) after surgery, the disease returned: 1 - residual tumor after surgery, 1 - relapse on the other side 1 year after surgery, 1 - newly developed invasive squamous cell carcinoma 10 years after primary surgery.